USFDA nod to Sun Pharma for its generic Ganirelix Acetate injection
- Country:
- India
Drug major Sun Pharmaceutical Industries Monday said it has received final approval from USFDA for its abbreviated new drug application (ANDA) for generic version of Ganirelix Acetate injection.
The generic version is therapeutic equivalent to Organon's Ganirelix Acetate injection, 250 mcg/0.5 ml.
Sun Pharma, including its subsidiaries and/or associate companies), announced that Sun Pharma has received final approval from USFDA for its abbreviated new Drug application (ANDA) for generic version of Ganirelix Acetate injection, 250 mcg/0.5 ml, the company said in a regulatory filing.
As per IQVIA, Ganirelix Acetate injection, 250 mcg/0.5 ml had annual sales of approximately USD 67 million in the US for the 12 months ended September 2018, the company said.
The commercialisation of this product in the US market is expected in Q4FY19, it added.
Shares of the company were trading at Rs 453.85, 7.81 per cent lower than its previous closing price.
(With inputs from agencies.)
- READ MORE ON:
- Abbreviated New Drug Application
- Owner's manual
- Market share
- Drug
- Pharmaceutical drug
- Chemical industry
- Pharmaceutical industry
- United States presidential approval rating
- President of the United States
- US market
- Organon's Ganirelix Acetate injection
- generic Ganirelix Acetate injection
- Drug major
- final USFDA nod
- Pharmaceutical Industries
- final approval
- previous closing price
- mcg
- Business News
- PTI News
Google News